Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 232975, 8 pages
http://dx.doi.org/10.1155/2014/232975
Research Article

Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls

1Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, 4 Pasteura Street, 50-367 Wroclaw, Poland
2Department of Radiology, Wroclaw Medical University, 68 Curie-Sklodowskiej Street, 50-369 Wroclaw, Poland
3Department of Health Promotion, University School of Physical Education, 35 Paderewskiego Street, 51-612 Wroclaw, Poland
4First Department of Gynaecology and Obstetrics, Wroclaw Medical University, 3 Chalubinskiego Street, 50-368 Wroclaw, Poland

Received 3 February 2014; Revised 7 May 2014; Accepted 17 June 2014; Published 17 July 2014

Academic Editor: Anil K. Agarwal

Copyright © 2014 Justyna Kuliczkowska Plaksej et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Diamanti-Kandarakis and A. G. Papavassiliou, “Molecular mechanisms of insulin resistance in polycystic ovary syndrome,” Trends in Molecular Medicine, vol. 12, no. 7, pp. 324–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Álvarez-Blasco, J. I. Botella-Carretero, J. L. San Millán, and H. F. Escobar-Morreale, “Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women,” Archives of Internal Medicine, vol. 166, no. 19, pp. 2081–2086, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Teede, A. Deeks, and L. Moran, “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan,” BMC Medicine, vol. 8, article 41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Vernon, A. Baranova, and Z. M. Younossi, “Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 3, pp. 274–285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Baranova, T. P. Tran, A. Birerdinc, and Z. M. Younossi, “Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 7, pp. 801–814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, pp. 1221–1231, 2002. View at Google Scholar
  7. M. M. Brzozowska, G. Ostapowicz, and M. D. Weltman, “An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 243–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. H. Kim and Z. M. Younossi, “Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome,” Cleveland Clinic Journal of Medicine, vol. 75, no. 10, pp. 721–728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. L. F. N. Zueff, W. P. Martins, C. S. Vieira, and R. A. Ferriani, “Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome,” Ultrasound in Obstetrics and Gynecology, vol. 39, no. 3, pp. 341–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Hossain, M. Stepanova, A. Afendy et al., “Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS),” Scandinavian Journal of Gastroenterology, vol. 46, no. 4, pp. 479–484, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. I. R. Dinu, S. G. Popa, M. MoţA et al., “The association of the rs1049353 polymorphism of the CNR1 gene with hypoadiponectinemia,” Romanian Journal of Morphology and Embryology, vol. 52, no. 3, pp. 791–795, 2011. View at Google Scholar · View at Scopus
  12. D. Osei-Hyiaman, M. DePetrillo, P. Pacher et al., “Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1298–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. K. M. Starowicz, L. Cristino, I. Matias et al., “Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet,” Obesity, vol. 16, no. 3, pp. 553–565, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. I. R. Dinu, S. Popa, M. Bîcu, E. Moţa, and M. Moţa, “The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects,” Romanian Journal of Internal Medicine, vol. 47, no. 1, pp. 9–18, 2009. View at Google Scholar · View at Scopus
  15. K. Eckardt, H. Sell, A. Taube et al., “Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle,” Diabetologia, vol. 52, no. 4, pp. 664–674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Mallat and S. Lotersztajn, “Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 294, no. 1, pp. G9–G12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. F. van Gaal, A. J. Scheen, A. M. Rissanen, S. Rössner, C. Hanotin, and O. Ziegler, “Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study,” European Heart Journal, vol. 29, no. 14, pp. 1761–1771, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. P. Després, A. Golay, and L. Sjöström, “Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2121–2134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. F. X. Pi-Sunyer, L. J. Aronne, H. M. Heshmati, J. Devin, and J. Rosenstock, “Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial,” Journal of the American Medical Association, vol. 295, no. 7, pp. 761–775, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Scheen, N. Finer, P. Hollander, M. D. Jensen, and L. F. van Gaal, “Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study,” The Lancet, vol. 368, no. 9548, pp. 1660–1672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Rosenstock, P. Hollander, S. Chevalier, and A. Iranmanesh, “SERENADE: the study evaluating rimonabant efficacy in drug-naive diabetic patients: effects of monotherapy with rimonabant, the first selective CB 1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes,” Diabetes Care, vol. 31, no. 11, pp. 2169–2176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Jeong, D. Osei-Hyiaman, O. Park et al., “Paracrine activation of hepatic cb1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver,” Cell Metabolism, vol. 7, no. 3, pp. 227–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Teixeira-Clerc, B. Julien, P. Grenard et al., “CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis,” Nature Medicine, vol. 12, no. 6, pp. 671–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. W. I. Jeong, D. Osei-Hyiaman, O. Park et al., “Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver,” Cell Metabolism, vol. 7, no. 3, pp. 227–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Gazzerro, M. G. Caruso, M. Notarnicola et al., “Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population,” International Journal of Obesity, vol. 31, no. 6, pp. 908–912, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Osei-Hyiaman, J. Liu, L. Zhou et al., “Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice,” Journal of Clinical Investigation, vol. 118, no. 9, pp. 3160–3169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Gary-Bobo, G. Elachouri, J. F. Gallas et al., “Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats,” Hepatology, vol. 46, no. 1, pp. 122–129, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Westerbacka, A. Kotronen, B. A. Fielding et al., “Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease,” Gastroenterology, vol. 139, no. 6, pp. 1961–1971, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Hézode, E. S. Zafrani, F. Roudot-Thoraval et al., “Daily cannabis Use: a novel risk factor of steatosis severity in patients with chronic hepatitis C,” Gastroenterology, vol. 134, no. 2, pp. 432–439, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. K. A. Alswat, “The role of endocannabinoids system in fatty liver disease and therapeutic potentials,” Saudi Journal of Gastroenterology, vol. 19, no. 4, pp. 144–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. R. El-Talatini, A. H. Taylor, J. C. Elson, L. Brown, A. C. Davidson, and J. C. Konje, “Localisation and function of the endocannabinoid system in the human ovary,” PLoS ONE, vol. 4, no. 2, Article ID e4579, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. M. Di Blasio, M. Vignali, and D. Gentilini, “The endocannabinoid pathway and the female reproductive organs,” Journal of Molecular Endocrinology, vol. 50, no. 1, pp. R1–R9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. R. El-Talatini, J. C. Elson, A. H. Taylor, and J. C. Konje, “The endocannabinoid, anandamide, is involved in human folliculogenesis and oocyte maturation during IVF treatment,” in Proceedings of the 2nd SGI International Summit in Reproductive Medicine—From Embryo and Endometrium to Implantation, p. 59, Valencia, Spain, 2007.
  34. L. L. Murphy, R. W. Steger, M. S. Smith, and A. Bartke, “Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat,” Neuroendocrinology, vol. 52, no. 4, pp. 316–321, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Matias, M. Gonthier, P. Orlando et al., “Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3171–3180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. F. J. Bermúdez-Silva, J. Suárez, E. Baixeras et al., “Presence of functional cannabinoid receptors in human endocrine pancreas,” Diabetologia, vol. 51, no. 3, pp. 476–487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. F. J. Bermúdez-Silva, J. Suárez Pérez, A. Nadal, and F. Rodríguez de Fonseca, “The role of the pancreatic endocannabinoid system in glucose metabolism,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 23, pp. 87–102, 2009. View at Google Scholar
  38. W. Kim, M. E. Doyle, Z. Liu et al., “Cannabinoids inhibit insulin receptor signaling in pancreatic β-cells,” Diabetes, vol. 60, no. 4, pp. 1198–1209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Pasquali, L. Patton, and A. Gambineri, “Obesity and infertility,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 14, no. 6, pp. 482–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Pasquali, A. Gambineri, and U. Pagotto, “The impact of obesity on reproduction in women with polycystic ovary syndrome,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 113, no. 10, pp. 1148–1159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Battista, N. Pasquariello, M. di Tommaso, and M. Maccarrone, “Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction,” Journal of Neuroendocrinology, vol. 20, no. 1, pp. 82–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. S. H. Saverymuttu, A. E. A. Joseph, and J. D. Maxwell, “Ultrasound scanning in the detection of hepatic fibrosis and steatosis,” British Medical Journal, vol. 292, no. 6512, pp. 13–15, 1986. View at Publisher · View at Google Scholar · View at Scopus
  43. X. Ma, N. S. Holalkere, R. A. Kambadakone, M. Mino-Kenudson, P. F. Hahn, and D. V. Sahani, “Imaging-based quantification of hepatic fat: methods and clinical applications,” Radiographics, vol. 29, no. 5, pp. 1253–1277, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. J. Brown, D. A. Tendler, R. G. McMurray, and T. L. Setji, “Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings,” Endocrine Practice, vol. 11, no. 5, pp. 319–324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Gambarin-Gelwan, S. V. Kinkhabwala, T. D. Schiano, C. Bodian, H. Yeh, and W. Futterweit, “Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome,” Clinical Gastroenterology and Hepatology, vol. 5, no. 4, pp. 496–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Jones, V. S. Sprung, C. J. A. Pugh et al., “Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 10, pp. 3709–3716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Markou, I. I. Androulakis, C. Mourmouris et al., “Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome,” Fertility and Sterility, vol. 93, no. 4, pp. 1220–1226, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. D. A. de Luis, M. González Sagrado, R. Aller, O. Izaola, R. Conde, and E. Romero, “G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2,” Nutricion Hospitalaria, vol. 25, no. 1, pp. 34–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. D. A. de Luis, M. González Sagrado, R. Aller, O. Izaola, and R. Conde, “Influence of G1359A polymorphism of the cannabinoid receptor gene on anthropometric parameters and insulin resistance in women with obesity,” Metabolism: Clinical and Experimental, vol. 60, no. 2, pp. 272–276, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Peeters, S. Beckers, I. Mertens, W. van Hul, and L. van Gaal, “The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men,” Endocrine, vol. 31, no. 2, pp. 138–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Frost, T. L. Nielsen, K. Wraae et al., “Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution,” European Journal of Endocrinology, vol. 163, no. 3, pp. 407–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. W. Lieb, A. K. Manning, J. C. Florez et al., “Variants in the CNR1 and the FAAH genes and adiposity traits in the community,” Obesity, vol. 17, no. 4, pp. 755–760, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. T. D. Müller, K. Reichwald, A. Wermter et al., “No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents,” Molecular Genetics and Metabolism, vol. 90, no. 4, pp. 429–434, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Völgyi, F. A. Tylavsky, A. Lyytikäinen, H. Suominen, M. Alén, and S. Cheng, “Assessing body composition with DXA and bioimpedance: effects of obesity, physical activity, and age,” Obesity, vol. 16, no. 3, pp. 700–705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Benzinou, J. Chèvre, K. J. Ward et al., “Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations,” Human Molecular Genetics, vol. 17, no. 13, pp. 1916–1921, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Zhuang, Y. Yang, F. Cao et al., “Associations of variants of CNR1 with obesity and obesity-related traits in Chinese women,” Gene, vol. 495, no. 2, pp. 194–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Russo, P. Strazzullo, F. P. Cappuccio et al., “Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 6, pp. 2382–2386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Schleinitz, S. Carmienke, Y. Böttcher et al., “Role of genetic variation in the cannabinoid type 1 receptor gene (CNR1) in the pathophysiology of human obesity,” Pharmacogenomics, vol. 11, no. 5, pp. 693–702, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Milewicz, U. Tworowska-Bardzińska, D. Jedrzejuk et al., “Are endocannabinoid type 1 receptor gene (CNR1) polymorphisms associated with obesity and metabolic syndrome in postmenopausal Polish women?” International Journal of Obesity, vol. 35, no. 3, pp. 373–377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. Ł. Łaczmański, A. Milewicz, K. Dunajska, D. Jedrzejczuk, M. Pawlak, and F. Lwow, “Endocannabinoid type 1 receptor gene (CNR1) polymorphisms (rs806381, rs10485170, rs6454674, rs2023239) and cardiovascular risk factors in postmenopausal women,” Gynecological Endocrinology, vol. 27, no. 12, pp. 1023–1027, 2011. View at Publisher · View at Google Scholar · View at Scopus